Search Results
Biotech in 2025: Opportunities Amid Uncertainty
A Podcast Conversation featuring Jane Ross and Michael Margolis
Sole Manager on the $247.31 Million Senior Living Revenue Bonds
Oppenheimer & Co. Inc. served as Sole Manager on the New Hope Cultural Education Facilities Finance Corporation’s $247.31 million Senior Living Revenue Bonds (Superior Living Foundation Project), Series 2025
2024 Private Placement Activity
Oppenheimer's update on VC, M&A, and BD&L activity for the biopharma sector.
2024 M&A and Strategic Collaborations
Oppenheimer's update on VC, M&A, and BD&L activity for the biopharma sector.
2025 Q1 Private Placement Activity
Oppenheimer's update on VC, M&A, and BD&L activity for the biopharma sector.
2025 Q1 M&A and Strategic Collaborations
Oppenheimer's update on VC, M&A, and BD&L activity for the biopharma sector.
Placement Agent on Helix Acquisition Corp. II's Private Placement Financing
Oppenheimer & Co. Inc. acted as Placement Agent on Helix Acquisition Corp. II’s $260MM Private Placement Financing in connection to the Business Combination with BridgeBio Oncology Therapeutics (BBOT)
Municipal Market 2025 Outlook: What We're Watching
Municipal Market 2025 Outlook: What We're Watching
Joint Bookrunner on Tarsus Pharmaceuticals Upsized Follow-On Offering
Oppenheimer & Co. Inc. acted as Joint Bookrunner on Tarsus Pharmaceuticals’ Upsized $143.7MM Follow-On Offering
Financial Adviser to Vandemoortele on its Acquisition of Lizzi srl.
Oppenheimer’s European Consumer Investment Banking Team is pleased to have acted as Financial Adviser to Vandemoortele on its acquisition of Lizzi srl.